BSD Medical Corp. develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. The company’s product lines include systems to treat cancer that have been in use for several years in the United States, Europe and Asia.
BSD Medical announced today that the US Food and Drug Administration (FDA) has granted the company a510(k) clearance to market its MicroThermX Microwave Ablation System (MTX-180) for ablation of soft tissue. The MTX-180 was designed to provide a higher power, optimized system targeted to the growing therapeutic interventional and surgical oncology market. The FDA approval authorizes the sale of the MTX-180 in the United States and approval in Europe is expected shortly.
BSD Medical’s MTX-180 provides minimally invasive access to the target tissue and can be in open surgical as well as in other ablation procedures used by both surgeons and radiologists. This new product will deliver targeted microwave energy to destroy soft tissue that is cancerous. Its primary competitive advantage is that it allows for larger and more uniform zones of ablation during a simple, single procedure.
The company believes that the global soft tissue ablation market is in excess of $2 billion and that its MTX-180 will be a major player in that market. The stock market today seems to be in agreement with the company’s assessment. BSD Medical’s stock closed trading at $2.91 up $1.84 or 162.83% for the day. The volume on this upsurge has been massive at about 27.2 million shares, which is in well in excess of the average daily volume of less than 100,000 shares.
For more information on BSD Medical and its MTX-180 system, visit the company’s website at www.BSDMedical.com.